University of California San Francisco, Department of Medicine , San Francisco, CA , USA.
Expert Opin Investig Drugs. 2014 Jul;23(7):1017-26. doi: 10.1517/13543784.2014.924504. Epub 2014 May 28.
The incidence and mortality related to acute heart failure (AHF) have increased in the recent decades despite clinical trials of multiple agents and considerable progress in cardiovascular disease overall.
This article reviews serelaxin , a new investigational drug in the treatment of AHF. It provides the background of the available treatments and focuses on serelaxin mechanisms, pharmacology, clinical features and its potential role in AHF.
Recent clinical trials of serelaxin (Pre-RELAX-AHF; RELAX-AHF) have provided a new hope in AHF. They have demonstrated significant serelaxin-related improvement in heart failure symptoms, length of hospital stay as well as mortality reduction in AHF patients. These findings were in the context of early administration in the course of AHF presentation in patients with normal or high blood pressures, thus highlighting the drug's strengths based on its molecular mechanisms of action. Overall, serelaxin is a promising therapy, and further studies aimed at reproducibility of prior results, safety and hemodynamic effects of serelaxin, as well as investigation of the molecular reasons for such effects are currently under way.
尽管在心血管疾病方面取得了相当大的进展，并且进行了多项药物临床试验，但近几十年来，与急性心力衰竭（AHF）相关的发病率和死亡率仍在上升。
本文回顾了治疗 AHF 的新型研究药物——松弛素。它提供了现有治疗方法的背景，并重点介绍了松弛素的作用机制、药理学、临床特征及其在 AHF 中的潜在作用。
松弛素的最近临床试验（Pre-RELAX-AHF；RELAX-AHF）为 AHF 提供了新的希望。它们表明，在 AHF 患者中，早期给药可显著改善心力衰竭症状、住院时间以及降低死亡率。这些发现是在正常或高血压患者 AHF 发作过程中进行的，因此强调了该药物基于其分子作用机制的优势。总的来说，松弛素是一种很有前途的治疗方法，目前正在进行旨在重现先前结果、研究松弛素的安全性和血液动力学作用以及探讨产生这种作用的分子原因的进一步研究。
